Related Experiment Video
Updated: Aug 14, 2026
Autonomous and Rechargeable Microneurostimulator Endoscopically Implantable into the Submucosa
Published on: September 27, 2018
EndoTAG-1. MediGene
1University Hospital Hamburg - Eppendorf, Department of Medicine - Oncology and Hematology, Martinstr 52, D-20246, Hamburg, Germany. schuch@uke.uni-hamburg.de
Abstract:
MediGene is developing EndoTAG-1, a formulation of paclitaxel encapsulated in positively charged lipid-based complexes, for the potential treatment of cancer. Phase II clinical trials in patients with advanced pancreatic cancer are ongoing.
Insights
MediGene is developing EndoTAG-1, a novel paclitaxel formulation, for advanced pancreatic cancer treatment. Phase II clinical trials are currently underway to evaluate its efficacy and safety in patients.
Area of Science:
- Oncology
- Nanomedicine
- Pharmaceutical Development
Background:
- Pancreatic cancer remains a significant challenge with limited effective treatment options.
- Paclitaxel is a widely used chemotherapy agent, but its delivery can be limited by toxicity and efficacy.
- Novel drug delivery systems are needed to improve the therapeutic index of existing chemotherapeutics.
Purpose of the Study:
- To evaluate the potential of EndoTAG-1, a novel paclitaxel formulation, for treating advanced pancreatic cancer.
- To assess the safety and efficacy of EndoTAG-1 in a Phase II clinical trial setting.
Main Methods:
- EndoTAG-1 is a formulation of paclitaxel encapsulated in positively charged lipid-based complexes.
- Phase II clinical trials are being conducted in patients with advanced pancreatic cancer.
Main Results:
- Clinical trial data is currently being collected and analyzed.
- Preliminary findings will inform further development and potential therapeutic applications.
Conclusions:
- EndoTAG-1 represents a promising targeted drug delivery approach for pancreatic cancer.
- Ongoing clinical trials are crucial for establishing the therapeutic value of this novel formulation.
